NASDAQ:BRKR - Bruker Stock Price, News, & Analysis

Bruker trades on the NASDAQ under the ticker symbol "BRKR."

Bruker declared a quarterly dividend on Friday, November 9th. Investors of record on Monday, December 3rd will be paid a dividend of $0.04 per share on Friday, December 21st. This represents a $0.16 annualized dividend and a yield of 0.54%. The ex-dividend date of this dividend is Friday, November 30th. View Bruker's Dividend History.

Bruker announced that its Board of Directors has initiated a share buyback program on Sunday, June 4th 2017, which allows the company to repurchase $225,000,000.00 in outstanding shares, according to EventVestor. This repurchase authorization allows the company to repurchase shares of its stock through open market purchases. Shares repurchase programs are generally a sign that the company's board believes its shares are undervalued.

Bruker Co. (NASDAQ:BRKR) released its quarterly earnings data on Thursday, November, 1st. The medical research company reported $0.37 earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of $0.30 by $0.07. The medical research company earned $466.60 million during the quarter, compared to analyst estimates of $451.88 million. Bruker had a return on equity of 27.46% and a net margin of 5.24%. The firm's revenue for the quarter was up 7.1% compared to the same quarter last year. During the same quarter in the prior year, the business posted $0.29 EPS. View Bruker's Earnings History.

Bruker is scheduled to release their next quarterly earnings announcement on Thursday, February 14th 2019. View Earnings Estimates for Bruker.

Bruker issued an update on its FY18 earnings guidance on Thursday, November, 1st. The company provided earnings per share (EPS) guidance of $1.36-1.40 for the period, compared to the Thomson Reuters consensus EPS estimate of $1.37. The company issued revenue guidance of $1.88-1.89 billion (+6.5-7%), compared to the consensus revenue estimate of $1.88 billion.

7 analysts have issued 1-year target prices for Bruker's stock. Their predictions range from $30.00 to $42.00. On average, they expect Bruker's stock price to reach $34.7143 in the next year. This suggests a possible upside of 17.2% from the stock's current price. View Analyst Price Targets for Bruker.

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Bruker in the last year. There are currently 2 sell ratings, 4 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Bruker.

News headlines about BRKR stock have been trending negative on Wednesday, according to InfoTrie. The research firm identifies negative and positive media coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Bruker earned a news sentiment score of -2.9 on InfoTrie's scale. They also assigned headlines about the medical research company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an effect on the stock's share price in the immediate future.

Some companies that are related to Bruker include Mettler-Toledo International (MTD), Waters (WAT), PerkinElmer (PKI), Bio-Rad Laboratories (BIO.B), Bio-Rad Laboratories (BIO), Coherent (COHR), Horiba (HRIBF), Pacific Biosciences of California (PACB), Accelerate Diagnostics (AXDX), Quanterix (QTRX), Fluidigm (FLDM), Eyepoint Pharmaceuticals (EYPT), Harvard Bioscience (HBIO), HTG Molecular Diagnostics (HTGM) and BioNano Genomics (BNGO).

Bruker's stock is owned by many different of retail and institutional investors. Top institutional investors include Vanguard Group Inc. (6.52%), Vanguard Group Inc (6.52%), FMR LLC (4.68%), BlackRock Inc. (3.41%), Acadian Asset Management LLC (2.98%) and AQR Capital Management LLC (1.44%). Company insiders that own Bruker stock include Frank H Laukien, Ingen Chris Van, Mark Munch and Richard Kniss. View Institutional Ownership Trends for Bruker.

BRKR stock was sold by a variety of institutional investors in the last quarter, including Marshall Wace North America L.P., Renaissance Technologies LLC, First Quadrant L P CA, Pictet Asset Management Ltd., Allianz Asset Management GmbH, MERIAN GLOBAL INVESTORS UK Ltd, Prudential Financial Inc. and First Trust Advisors LP. View Insider Buying and Selling for Bruker.

BRKR stock was purchased by a variety of institutional investors in the last quarter, including Janus Henderson Group PLC, Marshall Wace LLP, AQR Capital Management LLC, Panagora Asset Management Inc., Morgan Stanley, Man Group plc, Fuller & Thaler Asset Management Inc. and Epoch Investment Partners Inc.. View Insider Buying and Selling for Bruker.

Shares of BRKR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of BRKR stock can currently be purchased for approximately $29.62.

Bruker has a market capitalization of $4.55 billion and generates $1.77 billion in revenue each year. The medical research company earns $78.60 million in net income (profit) each year or $1.21 on an earnings per share basis. Bruker employs 6,200 workers across the globe.

The official website for Bruker is http://www.bruker.com.

Bruker's mailing address is 40 Manning Road, Billerica MA, 01821. The medical research company can be reached via phone at 978-663-3660 or via email at [email protected]